The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
It is intended for contrast enhancement in MRI scans
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Subscribe To Our Newsletter & Stay Updated
